Tag Archives: International Genomics Consortium

bioscience

Jewett Named Arizona Bioscience Leader of the Year

jewett-sqJack B. Jewett, President & CEO of the Flinn Foundation, will be honored with the Jon W. McGarity Arizona Bioscience Leader of the Year Award by the Arizona BioIndustry Association.

“Great leaders embrace possibilities and take the steps to make them reality. Jack B. Jewett has done more than just take steps,” shared Joan Koerber-Walker, President & CEO, of the Arizona Bioindustry Association. “Thanks to his leadership and the commitment of the Flinn Foundation, Arizona has a Bioscience Roadmap that charts our statewide bioscience strategies through 2025.”

A longtime Arizona leader in health care, education, and public policy, Mr. Jewett joined the Flinn Foundation in June 2009 as President & CEO. In this role, he is responsible for all grant programs and operations of the Flinn Foundation including Arizona’s Bioscience Roadmap, which is the longest running bioscience strategic initiative of its kind in the US. Under Jewett’s leadership, Flinn has renewed its commitment and released the next generation of the Roadmap extending out until 2025.

Mr. Jewett previously served in a variety of leadership roles within the private, public, and nonprofit sectors in Arizona for more than 40 years. He held senior public policy and government relations positions with Tucson Medical Center for 13 years and served as president of Territorial Newspapers, a family-owned publishing and printing company in Tucson. He served on the Arizona Board of Regents from 1998-2006, including a term as president; and five terms in the Arizona House of Representatives, from 1983-1992, the final two years as majority whip.

A University of Arizona graduate, Mr. Jewett currently serves on the board of trustees of the Tucson-based Thomas R. Brown Foundations, is a public member of the Arizona Judicial Council, and is a member of the Greater Phoenix Leadership Council. He served on the board of directors for the National Association of Governing Boards of Universities and Colleges from 2004-13, and received its Distinguished Service Award for outstanding trusteeship for his work on “Changing Directions,” an initiative of the Arizona Board of Regents.

The Flinn Foundation is a privately endowed, philanthropic grantmaking organization established in 1965 by Dr. Robert S. and Irene P. Flinn to improve the quality of life in Arizona to benefit future generations. Today, the Foundation supports the advancement of the biosciences in Arizona, as well as three other program areas to help build Arizona’s knowledge-driven economy.

A ceremony honoring Jack B. Jewett will take place at the AZBio Awards Sept. 17 at the Phoenix Convention Center. The AZBio Awards ceremony celebrates Arizona’s leading educators, innovators and companies. Each year, AZBio honors bioindustry leaders from across the state of Arizona who are illustrative of the depth, breadth and expertise of our bioscience industry.

Past recipients of the Jon W. McGarity Arizona Bioscience Leader of the Year Award include: Linda Hunt (Dignity Health), Harry George (Solstice Capital), Robert Penny, MD, PhD (International Genomics Consortium), Patrick Soon-Shiong, MD (NantHealth), Martin L. Shultz (Pinnacle West Capital Corp.), Michael Cusanovich, Ph.D., (University of Arizona), Jonathan Thatcher (Exeter Life Sciences), John W. Murphy (Flinn Foundation), and George Poste (Arizona State University).

For registration and more information, go to www.azbio.awards.com.

bioscience

Arizona bioscience industry producing ‘aha’ moments

AZBio Expo 2014 had “aha moments” at every turn. With over 250 entrepreneurs, innovators, business leaders, legislators, scientists and researchers in attendance, the energy was sizzling and the outlook endless. Here are just a few of the event highlights, appropriately, A to Z:

A – Access to Capital is the key. No money. No honey. Capital fuels innovation and commercialization. In the first panel discussion of the day – Funding Paths for Innovators – AZBio chief Joan Koerber-Walker engaged Mary Ann Guerra (BioAccel), Paul Jackson (Integrus Capital/Worthworm) and Kelly Slone (National Venture Capital Association) in a no-holds barred discussion. “The entire ecosystem has changed,” according to Slone. “After the tech bubble burst, available venture dollars have been virtually cut in half.” Guerra explains that only one in 100 will get angel funding – and then only one in 100 will get venture funding. We need to think of new ways to help our startup entrepreneurs get funding.” Jackson urges innovators to think like investors and offers one solution with his online valuation process, Worthworm.

B – Bridging the Gap with the 21st Century Cures Initiative. “No industry has to face the challenges we face to bring a product to market,” says Koerber-Walker. “We have new hope in the 21st Century Cures Initiative. Google it. Watch the videos, See what they are doing. There is exciting stuff happening and some of it is happening in Arizona.”

C — Cure Corridor. Scottsdale’s Mayor Jim Lane shares his pride and plans for the largest concentration of bioscience businesses in the U.S., the Cure Corridor, bounded on one side by the Scottsdale Airpark on the West, and the Fountain Hills Mayo facility on the East, “a major driver of our economy, with $2½ billion in direct economic impact and $3.5 billion in indirect impact.” According to Lane, “Health and wellness are a part of Scottsdale’s identity. We should never stop asking how we can find new answers alleviate pain, restore health and improve the quality of life.”

D – Discovery. Development. Delivery. Valley Fever Solutions CEO David Larwood shared his company’s formula for achieving success in development and funding – The Five R’s:

Right drug.
Right patient.
Right safety.
Right time. (How long before we can sell it?)
Right reimbursent.

E – Epigenetics and Personalized Medicine. Start-up company INanoBio founder and CEO Bharath Takupalli, explained that the genome sequencing market is expected to grow to $10 billion by 2020. With a unique capability to combine nanotechnology and biomedicine, his company is in the lead for building new solutions now. “We aim to develop a $100 ultrafast nanopore-based desktop sequencer – a point-of-care diagnostic” that will help change the face of healthcare, he explains.

F – Funding needs to be the focus for the future. According to a Flinn Foundation/Batelle report, “Arizona has many bioscience strengths and opportunities, but a substantial increase in private and public investment will be needed over the next decade to realize the [Flinn Foundation’s] Roadmap’s goals.” Last year, Arizona bioscience sector attracted $37 million in venture capital investment, up from $23 million from 2012, but that is only a fraction of the $9.8 billion invested nationally.

The goal is to increase the annual investment up to $40 million for seed capital in emerging companies and up to $125 million in venture capital.

G – Genomic advances hold high hopes for positively disruption. Explaining that healthcare premiums are growing at three times the rate of inflation and wages, Frederic Zenhausern, Ph.D., MBA, president of Whitespace Enterprise, says “The new era of precision healthcare (also called personalized healthcare) will provide more accessibility, transparency and health information to improve – dramatically – quality and lower cost over time.” His start-up company, based in Fountain Hills, develops methods for automating and miniaturizing the workflow processing of biological specimens.

H – Henry Ford.“I am looking for a lot of men who have an infinite capacity to not know what can’t be done,” said Henry Ford. So does Robert Penny, M.D., Ph.D., co-founder and CEO of the International Genomics Consortium and founder and CEO of Paradigm. “Phoenix has become the Grand Central Station for all the aggregating and analyzing cancer tissues. We have 10,000 tumors – and the information is publicly available. This will accelerate cancer discovery at a rate faster than ever,” he says. “This is a tidal wave that Arizona has led. Everyone in this room should be grabbing a surfboard and figuring out how to ride it.”

I – IPO: The nation’s top IPO of 2013 is right here in Chandler. With 380 percent growth in shareholder value, Insys Therapeutics, a commercial-stage specialty pharmaceutical company, ended the year with a market cap of $800 million. Darryl Baker, the chief financial officer, explained how the company, founded in 2002 by Dr. John Kapoor, was determined to discover better ways to deliver existing medications to patients. A sublingual fentanyl spray technology delivers treatments to opioid-tolerant cancer patients and holds real possibilities for better helping patients with acute pain, major burns and pediatric issues. In the R&D pipeline now is the development of a pharmaceutical cannabinoid, aimed at easing epilepsy, peripheral neuropathy and cocaine addiction.

J – Jobs: 107,000 bioscience jobs – good-paying and growing. Arizona has nearly 107,000 bioscience jobs, based on 2012 industry data, and the sector contributes an estimated $36 billion in revenue to the state’s economy, according to a study by the Ohio-based Battelle Technology Partnership Practice. Hospitals account for 83,000 of those jobs and $22 billion of the revenue. Arizona’s average annual wage in the bioscience sector is $62,775, 39 percent higher than the private-sector average, the report said. Not counting hospital jobs, the average wage for bioscience jobs jumps to $85,571. (2013 data).

K – Kalos Therapeutics is building a promising platform for future drug discovery. Start-up innovator Michael Kozlowski, OD, Ph.D., chief science officer of Kalos Therapeutics, explains that their focus on transforming the atrial natriuretic family of peptides engages a natural biochemical mechanism. This approach holds promise for people with pancreatic cancer because it results in a more complete response, reduced side effects and improved safety and a longer period of effectiveness.

L – Let’s leverage every resource, strength, collaboration and person we’ve got! Arizona’s bioscience industry is aiming to increase research revenue for institutions statewide by 69 percent over the next decade to $782 million and attract additional anchors for the sector.

M – Medtronic models aggressive, needs-focused growth. Keynote speaker Ron Wilson, vice president and general manager of the Medtronic Tempe campus made it clear that passion for people runs through his veins. Locating a small manufacturing facility here in 1973, the company’s facility today covers 30 acres, has 900 employees and generates $17 billion in revenues. How do they do it? We follow our founder’s vision still: We understand what the unmet needs are and we apply our knowledge for the good of people all over the world.”

N – Next Level. “Arizona has made unprecedented progress over the last decade in developing the talent, building research infrastructure, and growing its base. Taking it to the Next Level will require new collaborative partnerships, forward looking leaders, and aggressive investments from both the public and private private sectors to take our place in the top tiers globally,” shared Koerber-Walker. ”Now is our time. Let’s get it done!”

O – Orphans no more. Valley fever, considered an orphan disease, hits about 150,000 people a year – 60 percent live in central Arizona. Current treatments have major shortcomings, with about 60 percent of those treated being unresponsive. The result is 2,000 serious cases and 150 deaths a year. It affects pets in nearly equal proportion. David Larwood, CEO of Valley Fever Solutions, has some answers. His company is developing Nikkomycin Z (NikZ) as a dramatically superior potential cure for Valley Fever. To help raise awareness and prevention, the Arizona Board of Regents created Valley Fever Corridor project, a public health program led by University of Arizona College of Medicine’s John Galgiani, MD, who is also the chief medical officer for Valley Solutions.

P – Policymakers are on board. Gov. Jan Brewer’s time is coming to a close and it’s time to decide which candidate can bring their best to bioscience. Recognizing that the Arizona bioscience sector is growing at four times the rate of the national average, candidates Christine Jones, Doug Ducey, Fred Duval, Ken Bennett and Scott Smith shared their ideas on how to ramp up funding and revenues in 90-second videos. Koerber-Walker says, “The most important thing we can do this summer is vote in the primaries.”

Q – Cues: Here are a few Q’s for success. Some lessons learned, courtesy of Robert Penny:

Make sure you have:

Complementary skills and expertise
Trust
Interpersonal chemistry (It’s better to navigate bumps in the road with people you trust than people you don’t!)

Pick the right projects:

Big enough to be worthy of your efforts
Complex enough to need partnerships
Audacious enough to move the field

R – Remembering Polio: Can Looking Back Catapult Us Forward? How did we cure the world of polio? What did it take to conquer the most feared disease of the 20th Century? What threatens our world today and how can we continue to keep people healthy with the right vaccines, for the right person at the right time? Gaspar Laca, state government affairs director at GlaxoSmithKime, engaged David Larwood, CEO and president of Valley Fever Solutions (and a person who has been directly affected by polio) and Rep. Debbie McCune Davis, executive director of The Arizona Partnership for Immunization, in a rousing discussion of what’s happening in Arizona today, the mounting threats of the ”vaccine exemptors,” and what we need to do now. (See Vaccines.)

S – Shoes. Did you see those shoes? “Give a girl the right shoes and she can conquer the world!” Enough said.

T – Tucson’s Critical Path Institute creates new tools. A jewel in the bioscience crown – and located right here in Arizona! The Critical Path Institute (C-Path) is a breakthrough organization, creating a new movement: “consensus science.” Keynoter Martha Brumfield. Ph.D, president and CEO, shared what can be achieved when people come together with the belief that a “rising tide floats all boats.” Working to improve the unacceptable 95 percent failure rate in the testing of new drug therapies, C-Path is improving medical product development efficiencies by identifying pathways that integrate new scientific advances into the regulatory review process. Check out their Alzheimer’s clinical trial simulation tool.

U – United we stand. Mayors Jim Lane (City of Scottsdale) and John Lewis (Town of Gilbert) will join Koerber-Walker and an Arizona bioscience-business contingent next week at the 2014 BIO International Convention in San Diego (June 23-26), the world’s largest biotechnology gathering. They will surely scoop up new ideas, new connections – and with any luck, new investment!

V – Vaccines: Get ‘em! Talk about ‘em. Challenge the myths. Explain the realities. Polio. Measles. And whooping cough today. Without proper vaccinations, whooping cough (pertussis) could be the polio of our time. “As science-minded people, the best thing you can do is activate conversations about the importance of vaccinations. Here’s some help: Why immunize?

W – White Hat event brings in national investors. (Apply by July 15th.) “AZBio’s White Hat Investor’s Conference is the first ever life science specific investor conference to be held in Arizona,” says Koerber-Walker. “Kelly Slone [of the National Venture Capital Association] has been an amazing partner to bring this together along with the state bioscience association leaders from across the Rocky Mountain Southwest Region. Investors and investment firms from across the country will be here, so get involved. Even if you feel like you are not ready yet, take the leap and apply to present. “

X – “X” marks the spot for our next big gathering. Wear your White Hat! The West was won by innovators, investors, and prospectors who understood the value of discovery and accepted the challenge of investing in new frontiers. Meet a new generation of biotech and healthcare pioneers at White Hat Investors 2014, the first annual biotech and healthcare investor conference that showcases the best of the Rocky Mountain & Southwest Region.

Bioindustry Associations from across the Rocky Mountain and Southwest Region are coming together to present an opportunity for Angels, Venture Capitalists and Strategic Investors to connect with the best biotech and healthcare investment opportunities from across the Rocky Mountain & Southwest states at White Hat Investors 2014 in Phoenix, Arizona on September 17 & 18, 2014.

Presenting Companies will be selected from the region’s emerging innovator leaders in the fields of:

Diagnostics
Therapeutics
Medical Devices
Health IT

Y – Young Talent is being cultivated. We got it! With nearly 50 abstracts accepted and student presenters presenting at the Expo, Koerber-Walker got it right when she said, “These young people are going to be working on things that we can’t even begin to imagine!” Arizona’s tremendous mentoring people and organizations are sharing knowledge, support and inspiration. For example University of Arizona student Keeley Brown is destined to help the world crack the code on genetically modified foods and farming. (Her presentation was the “Epigenetic Effects of Transgenic Manipulation in Glycine Max (Soybeans).

Zzzzzzzzz – No one fell asleep at this conference! Catherine Leyen, founder and CEO of start-up RadiUp, says she comes to AZBio to stay abreast of the action, connect with like-minded people and soak up inspiration. Her verdict of AZBIO Expo 2014? Mission accomplished!

90679955

Phoenix Pathologist Earns Distinguished Patient Award

The College of American Pathologists (CAP) awarded Robert J. Penny, MD, PhD, FCAP, from Phoenix, the CAP Distinguished Patient Care Award at a special ceremony held in San Diego on September 8, 2012, at CAP ’12 — THE Pathologists’ Meeting.

Dr. Penny was recognized for his extensive scientific translational research to accelerate the adoption of molecular pathways and associated therapies into the field of pathology and oncology to improve the lives of cancer patients.

“I am deeply honored to be recognized by my peers with the CAP Distinguished Patient Care Award,” said Dr. Penny. “As pathologists, we are the current and future innovators to drive molecular pathways and their associated therapies into clinical medicine. My work recognized here is a very small start to a remarkable future for the patients of tomorrow.”

Dr. Penny is the co-founder and chief executive officer of the International Genomics Consortium (IGC) in Phoenix. While at IGC, he began the national Expression Project for Oncology (expO), which provides a free public gene expression database of 2,000 cancers with clinical outcomes for translation. The National Institutes of Health cited expO’s success as critical in deciding to launch The Cancer Genome Atlas (TCGA), a national project to improve the prevention, diagnosis, and treatment of cancer.

Also while at IGC, he founded the Molecular Profiling Institute and served as its first chief executive officer and chairman of the board. Dr. Penny’s vision was to bring to surgical pathology a holistic, evidenced-based, integrated molecular pathway analysis with accompanying therapies provided by pathologists for oncologists. He developed the Molecular Profiling Institute’s portfolio of molecular testing and pharmaceutical services, which includes his successful commercially available holistic genomic analysis of cancer with its award-winning surgical oncology report (Target Now) that matches molecular mechanisms with associated oncology therapies. The test has been paradigm changing. Patients who failed rounds of chemotherapy frequently benefited from the targeted therapy. Today, tens of thousands of patients annually use the test throughout the United States.

Dr. Penny is a recognized expert in the translation of diagnostics into patient care as well as in creating high-quality biorepositories. He has established two national esoteric reference medical laboratories, a national tissue bank and analysis center, and a national genomics program to help accelerate the translation of new diagnostics. He has helped bring cellular and molecular diagnostic, prognostic, and therapeutic testing to patient care throughout the nation with leukemia, lymphoma, and solid tumors.
Dr. Penny received his BS, MS, PhD (genetics), and MD from the University of Arizona and then went on to receive his pathology training at Harvard’s Brigham & Women’s Hospital in Boston, where he served as chief resident and completed fellowships in hematopathology and surgical pathology. Dr. Penny’s contributions include a textbook in oncology, publication of articles, and leadership roles in laboratory management.
The College of American Pathologists (CAP), celebrating 50 years as the gold standard in laboratory accreditation, is a medical society serving more than 18,000 physician members and the global laboratory community. It is the world’s largest association composed exclusively of board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care.

blue-dna-istock_000005649360small-step-32

International Genomics Consortium forms joint venture with Michigan

As a key step toward providing patients with treatments based on their own DNA profiles, the International Genomics Consortium (IGC) and the University of Michigan have launched a new joint venture that will help usher in an age of personalized medicine.

Called Paradigm, the new nonprofit company brings together the expertise of IGC and the U-M Health System, two leaders in using genetic information to understand and treat disease.

Beginning with cancer and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics.  The company will also help support clinical trials at UMHS and other healthcare systems.

Paradigm is being formed under the Michigan Health Corporation, the part of UMHS that enables outside partnerships. The company will have a presence in Phoenix and Ann Arbor.

“Paradigm builds on our ever-increasing understanding of the interplay of multiple disease-causing genes and how this affects sensitivity to specific treatment regimens,” says Robert Penny, M.D., Ph.D., the chief executive officer and co-founder of Paradigm and IGC, which was formed by veteran genetic researchers and played a key role in compiling The Cancer Genome Atlas, a catalog of genes known to be involved in cancer. “We will bring our expertise to bear to create true personalized medicine options for clinicians and their patients.”

“We’re thrilled to take this important step that allows us to harness the power of genetic information to guide patient therapy and improve outcomes,” says Jay Hess, M.D. Ph.D., M.H.S.A.,chair of the Department of Pathology at the U-M Medical School and a co-founder of Paradigm. “IGC has a proven track record of bringing molecular diagnostics to market, yet shares our nonprofit patient-focused vision.”

“Through this new venture, we will continue our leadership role supporting and translating cutting edge medical research to improve patient care,” said David Mallery, J.D., M.B.A., the president and co-founder of Paradigm and IGC.

Initially, Paradigm will focus on offering services to oncologists and oncology groups, pathologists, academic medical centers and clinical trial groups studying personalized medicine regimens. Its first products will be especially of use in better tailoring treatments for cancer patients.

“The International Genomics Consortium played a pivotal role in ushering in Arizona’s bioscience initiative in 2002 and has continued to be a leader in the industry. Over the years, IGC has provided Arizona with federal research grants, successful commercial ventures, and high-quality jobs while contributing to the advancement of human medicine,” said Jack B. Jewett, president and CEO of the Flinn Foundation.  “This collaboration among two outstanding national institutions demonstrates Arizona’s leadership in molecular medicine and is a testament to both IGC’s and Arizona’s stature in the biosciences nationally.”

“With the University of Michigan Health System as our partner in Paradigm, IGC strengthens its revolutionary role in gene-based research, making our country more competitive internationally and keeping Maricopa County at the forefront of personalized medicine,” said Richard Mallery, Founding Chair of IGC.

University of Arizona College of Medicine

UA College Of Medicine Health Sciences Education Building Celebrates “Topping Out”

Health Sciences Education Building, UA College of MedicineA major Downtown Phoenix development project hit a big milestone October 5, 2011 with the “topping out” of construction of the Health Sciences Education Building on the campus of the University of Arizona College of Medicine.

The final beam of the building was ceremoniously lifted and secured at its highest point with workers and college staff and faculty celebrating midday Wednesday.

The $129M, 264,000 SF building – being built in a joint venture by DPR Construction and Sundt Construction, Inc. – will allow the state to take the next step in expanding its medical education facilities.

The new six-story building will house administrative offices, lecture halls, classrooms, class laboratories and a learning resource center. CO Architects is the design and executive architect; Ayers Saint Gross is associate architect and master planner.

The College of Medicine-Phoenix plans to expand its class size and add instruction as Northern Arizona University will also bring a physician’s assistant and physical therapy programs to the Health Sciences Education Building. 


In its fifth year in Downtown Phoenix, the College of Medicine currently anchors the campus with 192 medical students, admitting 48 per year. After the completion of the Health Sciences Education Building in 3Q 2012, the university plans to admit up to 80 students per class and eventually reach a capacity of 120 per class to address the critical need for physicians in Arizona.

Also on the Phoenix Biomedical Campus are the UA College of Pharmacy and the Mel and Enid Zuckerman College of Public Health, the headquarters of the Translational Genomics Research Institute and International Genomics Consortium, and Arizona Biomedical Collaborative building.

For more information about the Health Sciences Education Building, visit ahsc.arizona.edu.

Health Sciences Education Building, UA College of Medicine

Good Samaritan Hospital - AZ Business Magazine Mar/Apr 2011

Arizona’s Health Care Industry Has Flourished From Cottages To World-Class Facilities

A Century of Care

From cottages to world-class facilities, Arizona’s health care industry has flourished

Mayo Clinic Hospital - AZ Business Magazine Mar/Apr 2011 In the nearly 100 years since Arizona became a state, the health care sector has become a powerful economic force.

According to a study by Arizona State University’s L. William Seidman Research Institute, Arizona’s hospital community alone employs more than 80,000 people and contributes $11.5 billion to the gross state product. Indirectly, hospitals create about 120,000 additional jobs, more than the combined populations of Coconino, Graham and Santa Cruz counties.

Sisters of Mercy

It all started some 17 years before statehood in January 1895, when the Sisters of Mercy had collected enough money to rent a six-bedroom cottage at Fourth and Polk streets in Downtown Phoenix. Each room was equipped with two beds for TB patients, and thus was born St. Joseph’s Sanitarium, predecessor of St. Joseph’s Hospital and Medical Center and the first hospital in Phoenix. Downtown Phoenix 1900s - AZ Business Magazine Mar/Apr 2011

In the mid-1940s, the nuns purchased 10 acres at Third Avenue and Thomas Road, which was part of an old dairy farm. Today, St. Joseph’s is a 670-bed, not-for-profit hospital that is one of the cornerstones of the state’s health care industry.

A second giant in health care, Good Samaritan Hospital of Phoenix, launched its first facility in an apartment building at Third Street near Van Buren in 1911. Initially incorporated as the Arizona Deaconess Hospital and Home, it opened with 15 beds.

One-hundred years later, Banner Good Samaritan Medical Center in Downtown Phoenix is the flagship of Banner Health, with more than 662 licensed patient care beds. Banner Good Samaritan employs more than 4,200 health care professionals and support staff. Nearly 1,700 physicians representing more than 50 specialties work with Banner Good Samaritan staff to care for more than 43,000 inpatients a year.

Another early entry in the health care scene was the State Asylum for the Insane, which was rebuilt after a fire in 1911. In 1924, the asylum was informally renamed Arizona State Hospital.

Established in 1943 as a community hospital, Tucson Medical Center is among the 300 largest hospitals in the country. It is licensed for 650 adult and skilled nursing beds, and serves more than 30,000 inpatients and 122,000 outpatients a year.

St. Luke Hospital - AZ Business Magazine Mar/Apr 2011In 1971, University Medical Center — a private, nonprofit hospital located at the Arizona Health Sciences Center adjacent to the University of Arizona in Tucson — was established. UMC is Arizona’s only academic medical center, and earlier this year it became an international focal point for neurosurgery and trauma care after a gunman shot and wounded U.S. Rep. Gabrielle Giffords (D-Ariz.) and killed six people.

In Northern Arizona, the Flagstaff Medical Center, a not-for-profit hospital, was founded in 1936. A part of the Northern Arizona Healthcare family, it has some 270 beds and its medical staff includes about 200 physicians. Among its specialties are cancer, heart and sports medicine.

Health care continues to be a concern on Indian reservations throughout Arizona, particularly in some of the remote regions. A relatively new program, the American Indian Research Center for Health is designed to improve the health status of Native Americans and increase the number of Native American scientists and health professionals engaged in research. Classes for the student-training component of the program are held at the University of Arizona.

Read more…